Palazestrant

Drug identity checked against registry records

Also recorded as OP-1250

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767—Phase 3Recruiting2028-12Estimated
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738OLMAPhase 3Active not recruiting2026-10-31Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.